title: [The effect of IRESSA on H22 mouse hepatocellular carcinoma].
abstract: OBJECTIVE
  To investigate the effect of IRESSA (gefitinib, ZD1839) on H22 murine hepatocellular carcinoma.
  
  
  METHODS
  Mice bearing H22 hepatocellular carcinoma were randomly divided into oral control group, Normal saline (NS) control group, cisplatin (CDDP) d1-5 group, CDDP d6-10 group, IRESSA group, IRESSA combined with CDDP early (IRESSA + CDDP d1-5) group, and IRESSA combined with CDDP lately (IRESSA + CDDP d6-10) group. IRESSA was given by daily gastrogavage for 10 days (day 1-day 10) at 100 mg/kg in body weight (BW). CDDP was given by daily intraperitoneal injection for 5 days (day 1-day 5, or day 6-day 10) at 1.2 mg/kg in BW. The growth inhibiting rate (IR) of tumor, change of BW, spleen index (SI), and amounts of blood leucocyte or hemoglobin were detected.
  
  
  RESULTS
  IR of tumor in IRESSA group was not significantly difference with that in CDDP d1-5 group, CDDP d6-10 group, IRESSA + CDDP d1-5 group (P > 0.05). IR of tumor in IRESSA group, CDDP d1-5 group, CDDP d6-10 group, IRESSA and IRESSA + CDDP d1-5 group were 41%, 54%, 46%, and 56%, respectively. IR of tumor in IRESSA + CDDP d6-10 group (26%) was significantly lower than that in CDDP d6-10 group (P < 0.05) or in IRESSA + CDDP d1-5 group (P < 0.01). Compared with oral or NS control groups, SI and net BW in IRESSA group was not significantly difference (P > 0.05). SI and net BW in both IRESSA + CDDP d1-5 group and IRESSA + CDDP d6-10 group were lower markedly than those in IRESSA group (P < 0.01).
  
  
  CONCLUSIONS
  Tumor growth of H22 bearing mice was markedly inhibited by IRESSA.
authors.affiliation: School of Oncology, Peking University and Beijing Institute for Cancer Research, Beijing Cancer Hospital, Beijing 10036, China.
authors.forename: Bu-dong
authors.initials: BD
authors.lastname: Zhu
authors.forename: Shou-jun
authors.initials: SJ
authors.lastname: Yuan
authors.forename: Jian-ming
authors.initials: JM
authors.lastname: Xu
authors.forename: Qi-cheng
authors.initials: QC
authors.lastname: Zhao
authors.forename: Xin
authors.initials: X
authors.lastname: Li
authors.forename: Yan
authors.initials: Y
authors.lastname: Li
authors.forename: Li-hua
authors.initials: LH
authors.lastname: Hao
mesh_terms: D000818:Animals; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D006528:Carcinoma, Hepatocellular / Q000188:drug therapy*; D002945:Cisplatin / Q000627:therapeutic use; D004195:Disease Models, Animal; D000077156:Gefitinib; D008113:Liver Neoplasms / Q000188:drug therapy*; D051379:Mice; D011799:Quinazolines / Q000627:therapeutic use*; D011897:Random Allocation; D016896:Treatment Outcome
chemical_list: D000970:Antineoplastic Agents; D011799:Quinazolines; D002945:Cisplatin; D000077156:Gefitinib